Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026
Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals Medical Device

JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion

Fineline Cube Jun 14, 2023

China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai...

Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Company Drug

Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study

Fineline Cube Jun 14, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...

Company Drug

Croma-Pharma Initiates Phase III Clinical Trial in China for Hyaluronic Acid Dermal Filler

Fineline Cube Jun 13, 2023

Austria-based Croma-Pharma has revealed that the first patient is set to be enrolled in a...

Company Deals R&D

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

Fineline Cube Jun 13, 2023

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...

Company Deals

Apeloa Pharmaceutical Partners with Zelgen Biopharmaceuticals for CDMO Programs

Fineline Cube Jun 13, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Drug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

Fineline Cube Jun 13, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...

Company Drug

Bio-Thera Solutions’ BAT6026 Receives NMPA Approval for Atopic Dermatitis Clinical Trials

Fineline Cube Jun 13, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced receiving approval from China’s National Medical Products...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...

Company Drug

CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study

Fineline Cube Jun 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Deals

VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities

Fineline Cube Jun 13, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...

Company Drug

China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures

Fineline Cube Jun 13, 2023

China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China

Fineline Cube Jun 13, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...

Company Drug

Abbisko Therapeutics Initiates Phase II Study for Pimicotinib in Chronic Graft-Versus-Host Disease

Fineline Cube Jun 12, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing...

Policy / Regulatory

NHSA Launches 2023 NRDL Update Process with New Work Plan and Public Feedback Period

Fineline Cube Jun 12, 2023

The National Healthcare Security Administration (NHSA) has commenced the process for the annual update of...

Company Drug

Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA

Fineline Cube Jun 12, 2023

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...

Company Drug

CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment

Fineline Cube Jun 12, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Drug

Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment

Fineline Cube Jun 12, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...

Company Deals

Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China

Fineline Cube Jun 12, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Posts pagination

1 … 471 472 473 … 622

Recent updates

  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
  • Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
  • Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.